🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Prevention of NAFLD and CVD Through Lifestyle Intervention

RecruitingNAAges 45 Years - 60 YearsAllPontificia Universidad Catolica de Chile
NCT05618626 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Prevention of non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) through lifestyle intervention (MAUCO+) is a clinical trial that aims to improve sarcopenia, aerobic capacity, body composition, and lipid profile, insulin resistance, cardiovascular risk, NAFLD, and maintain a healthier lifestyle. Through the implementation of physical activity and nutritional programs.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * With and without gallstones disease * With various degrees of NAFLD (none too severe) Exclusion Criteria: * Any significant comorbidity or physical limitation to undergo resistance exercise program * Use of medications that alter muscle mass (e.g., corticosteroids) * History of hepatitis B or C * Use of hepatotoxic drugs
💊

What it tests

  • Physical exercise and dietary intervention for NAFLD
📍

Where

1 site
Centro MAUCO+
Molina, Chile
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy